Resolution of transfusion dependence by recombinant human erythropoietin (rHuEPO) in acquired pure red cell aplasia (PRCA) associated with myeloid metaplasia.
A patient with acquired pure red cell aplasia and agnogenic myeloid metaplasia (AMM) was treated with rHuEPO. She became transfusion independent. Weekly injections of rHuEPO have maintained the response without side-effects or disease progression. In addition, marrow fibrosis and splenomegaly have decreased. Therefore, rHuEPO may be effective therapy for some patients with acquired PRCA and/or AMM.
Zeigler
Z R
ZR
Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh 15224.
Rosenfeld
C S
CS
Shadduck
R K
RK
D000368:Aged; D001803:Blood Transfusion; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D055728:Primary Myelofibrosis / Q000150:complications; D012010:Red-Cell Aplasia, Pure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012156:Reticulocytes; D013997:Time Factors
D004921:Erythropoietin